We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$918M
AUM Growth
+$52.7M
Cap. Flow
-$46.8M
Cap. Flow %
-5.1%
Top 10 Hldgs %
48.26%
Holding
70
New
15
Increased
16
Reduced
21
Closed
16
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$38.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$29.8M
3
AZN icon
AstraZeneca
AZN
+$18.5M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$18.5M
5
BIIB icon
Biogen
BIIB
+$13.9M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$39.5M
2
HCA icon
HCA Healthcare
HCA
+$23.2M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$20.9M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$18.8M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.78%
2 Miscellaneous 9.3%
3 Technology 2.51%
4 Communication Services 1.69%
5 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MODN icon
26
DELISTED
MODEL N, INC.
MODN
$15.5M 1.69%
1,461,678
+4,400
+0.3% +$44.6K
2013 Q4
4 quarters
UHS icon
27
Universal Health Services
UHS
$11B
$15.1M 1.64%
135,270
+11,478
+9% +$1.21M
2014 Q2
2 quarters
CIVI icon
28
DELISTED
Civitas Solutions, Inc.
CIVI
$15M 1.63%
879,485
+260,249
+42% +$4.11M
2014 Q3
1 quarter
BIIB icon
29
Biogen
BIIB
$34.8B
$14.6M 1.59%
+43,113
New +$13.9M
2014 Q4
0 quarters
CSLT
30
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$14.6M 1.59%
1,247,268
-436,549
-26% -$5.21M
2014 Q1
3 quarters
OXFD
31
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$14.6M 1.59%
1,070,995
+4,580
+0.4% +$62.6K
2013 Q4
4 quarters
GMED icon
32
Globus Medical
GMED
$10.6B
$14.5M 1.58%
611,731
-354,569
-37% -$7.85M
2013 Q2
6 quarters
ARAY icon
33
Accuray
ARAY
$20.8M
$11.6M 1.26%
1,535,475
-117,653
-7% -$830K
2013 Q3
5 quarters
AKAO
34
DELISTED
Achaogen Inc
AKAO
$9.58M 1.04%
733,953
-36,469
-5% -$371K
2014 Q1
3 quarters
BLUE icon
35
DELISTED
bluebird bio
BLUE
$9.38M 1.02%
+7,892
New +$5.27M
2014 Q4
0 quarters
NVRO icon
36
DELISTED
NEVRO CORP.
NVRO
$9.06M 0.99%
+234,254
New +$7.38M
2014 Q4
0 quarters
CNXR
37
DELISTED
Connecture, Inc.
CNXR
$8.5M 0.93%
+943,000
New +$8.46M
2014 Q4
0 quarters
ATRA icon
38
Atara Biotherapeutics
ATRA
$96.9M
$7.07M 0.77%
+10,571
New +$6.46M
2014 Q4
0 quarters
EHTH icon
39
eHealth
EHTH
$19.4M
$6.6M 0.72%
264,942
+87,154
+49% +$2.12M
2014 Q3
1 quarter
FLXN icon
40
DELISTED
Flexion Therapeutics, Inc.
FLXN
$6.36M 0.69%
315,144
-150,789
-32% -$2.73M
2014 Q1
3 quarters
ELDN icon
41
Eledon Pharmaceuticals
ELDN
$184M
$3.17M 0.35%
1,328
-1,230
-48% -$2.92M
2014 Q3
1 quarter
CARM icon
42
DELISTED
Carisma Therapeutics
CARM
$2.85M 0.31%
+12,000
New +$2.69M
2014 Q4
0 quarters
PACB icon
43
Pacific Biosciences
PACB
$609M
$1.87M 0.2%
+237,977
New +$1.52M
2014 Q4
0 quarters
LOXO
44
DELISTED
Loxo Oncology, Inc
LOXO
$1.62M 0.18%
137,681
-402,619
-75% -$4.69M
2014 Q3
1 quarter
FWP
45
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$526K 0.06%
+3,605
New +$520K
2014 Q4
0 quarters
CLDX icon
46
Celldex Therapeutics
CLDX
$2.27B
$476K 0.05%
+1,740
New +$433K
2014 Q4
0 quarters
PPH icon
47
VanEck Pharmaceutical ETF
PPH
$1.07B
$418K 0.05%
6,500
– –
2013 Q2
6 quarters
WCG
48
DELISTED
Wellcare Health Plans, Inc.
WCG
$401K 0.04%
4,887
-220,146
-98% -$15.3M
2014 Q3
1 quarter
QQQ icon
49
Invesco QQQ Trust
QQQ
$487B
$355K 0.04%
+3,434
New +$347K
2014 Q4
0 quarters
IBB icon
50
iShares Biotechnology ETF
IBB
$10.6B
$303K 0.03%
3,000
-1,956
-39% -$190K
2014 Q2
2 quarters
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2014 Portfolio in Review

As of Q4 2014, Redmile Group held 70 positions worth $918M, up 6.1% from $866M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group withdrew a net $46.8M in Q4 2014, closing 16 positions and reducing 21 holdings. Its most notable exit was Allergan plc, an estimated $39.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Gilead Sciences worth $34.7M.

  • Redmile Group's largest Q4 2014 buy was Gilead Sciences: 368,615 shares worth $34.7M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q4 2014, an estimated $29.8M increase.
  • Redmile Group's biggest Q4 2014 reduction was Wellcare Health Plans, Inc., cutting an estimated $15.3M.
  • Redmile Group fully exited Allergan plc in Q4 2014, selling an estimated $39.5M.
  • Redmile Group's ten largest holdings make up 48% of its $918M portfolio in Q4 2014.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2014.
  • Redmile Group's portfolio value rose 6.1% quarter-over-quarter to $918M.

Based on Redmile Group's 13F filing for Q4 2014, filed 18 Feb 2015.